Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Depreciation & Amortization (CF) (2016 - 2025)

Rockwell Medical's Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $546000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 0.55% year-over-year to $546000.0; the TTM value through Dec 2025 reached $2.2 million, up 0.55%, while the annual FY2025 figure was $2.2 million, 0.55% up from the prior year.
  • Depreciation & Amortization (CF) reached $546000.0 in Q4 2025 per RMTI's latest filing, roughly flat from $544000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $564000.0 in Q3 2023 to a low of $133000.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $353000.0, with a median of $370500.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 39.55% in 2021, then soared 294.41% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $133000.0 in 2021, then rose by 15.79% to $154000.0 in 2022, then surged by 257.14% to $550000.0 in 2023, then fell by 1.27% to $543000.0 in 2024, then rose by 0.55% to $546000.0 in 2025.
  • Per Business Quant, the three most recent readings for RMTI's Depreciation & Amortization (CF) are $546000.0 (Q4 2025), $544000.0 (Q3 2025), and $563000.0 (Q2 2025).